# Cannabinoid Clinical Trials: CBD, Psychosis & Brain Function > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/cbd-hippocampal-glutamate-modulation-psychosis-risk/ > **Published:** 2026-03-03T21:42:01-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T12:01:14-04:00 > **Clinical Summary:** Explore CBD hippocampal glutamate modulation and its impact on brain function in clinical trials for psychosis risk and cognitive health. --- #### Clinical Takeaway In a study of individuals at clinical high risk for psychosis, a single dose of CBD influenced the relationship between hippocampal glutamate levels and prefrontal brain activity during verbal memory tasks. These findings suggest CBD may act on measurable neurochemical and functional brain abnormalities that are present before psychosis fully develops. The results add to growing evidence that CBD has identifiable biological effects in at-risk populations, though clinical implications require further investigation. ### #17 A single dose of cannabidiol modulates the relationship between hippocampal glutamate and learning-related prefrontal activation in individuals at Clinical High Risk of Psychosis. **Citation:** Shi Yiling et al. *A single dose of cannabidiol modulates the relationship between hippocampal glutamate and learning-related prefrontal activation in individuals at Clinical High Risk of Psychosis.* Psychiatry research. Neuroimaging. 2026. PMID: 41337954. **Study type:** Journal Article, Randomized Controlled Trial  |  **Topic area:** Cannabidiol  |  **CED Score:** 10 Design: 5 Journal: 0 N: 1 Recency: 3 Pop: 2 Human: 1 Risk: -2 Why This Matters This study elucidates a potential mechanistic pathway by which CBD may exert neuroprotective effects in CHR populations, specifically by modulating the glutamate-dependent coupling between hippocampal and prefrontal circuits that are implicated in psychotic progression. Understanding how CBD normalizes this neurotransmitter-brain activation relationship at a single-dose level could inform pharmacological strategies to prevent or delay transition to psychotic disorder in vulnerable individuals. The findings may support CBD’s development as a disease-modifying intervention rather than merely a symptomatic treatment, which would represent a significant advancement in early psychosis management. **Quality Gate Alerts:** - Preclinical only **Methodological Considerations:** - Small sample — underpowered for subgroup analysis **Abstract:** BACKGROUND: Cannabidiol (CBD) is being studied as a potential intervention for the people at clinical high risk for psychosis (CHR), though the mechanisms underlying its effects are not fully understood. Previous studies indicate that a single dose of CBD can normalize alterations in memory-related brain activation and modulate hippocampal glutamate levels in the early stages of psychosis. This study aimed to examine the acute effects of CBD on the relationship between hippocampal glutamate levels and brain activation during verbal memory in individuals at CHR. METHODS: A total of thirty-three participants (n = 33) at CHR were randomly assigned to receive a single 600 mg dose of CBD (CHR-CBD) or a placebo capsule (CHR-PLB). Age-matched healthy controls (HC) (n = 19) received no study drugs. Participants underwent MRI scanning while performing a verbal learning task, and proton magnetic resonance spectroscopy to measure hippocampal glutamate levels. Effect of group x hippocampal glutamate interactions on brain activation was tested. RESULTS: CHR-PLB showed positive correlation between hippocampal glutamate levels and dorsolateral prefrontal cortex (dlPFC) (Pcorr. = 0.0039) activation compared to HC during both verbal encoding and recall. Under a single dose of CBD, the glutamate-dlPFC activation relationship was negative and significantly different compared to placebo in CHR individuals (Pcorr. = 0.0001) during both verbal encoding and recall. The reversed correlation in CBD group was also observed in the parahippocampal gyrus (Pcorr. = 0.0022) and amygdala (Pcorr. = 0.0019) during verbal recall. CONCLUSIONS: These findings suggest that CBD may normalise disrupted hippocampal-prefrontal glutamatergic coupling in CHR, highlighting its potential to target the neurochemical mechanisms underlying [cognitive impairment](https://cedclinic.com/acute-effects-partial-cb1-receptor-agonists-cognition/). Clinical Perspective This mechanistic study provides intriguing preliminary evidence that a single CBD dose may influence glutamate-mediated neurotransmission in individuals at clinical high risk for psychosis, specifically by modulating the interaction between hippocampal glutamate and prefrontal learning circuits. However, several important caveats merit consideration: the sample size appears limited, a single acute dose may not reflect effects of sustained treatment, and the relationship between observed neurobiological changes and clinically meaningful outcomes such as psychosis prevention remains unclear. Additionally, the study does not address potential individual variability in CBD metabolism, concurrent medication interactions, or how findings in a CHR population might generalize to established psychotic disorders. Despite these limitations, the work aligns with mechanistic hypotheses suggesting CBD’s neuroprotective effects may operate through glutamate modulation, which could inform future trials examining whether targeted CBD dosing during critical windows of psychosis risk might help preserve [cognitive function](https://cedclinic.com/reverse-cholesterol-transport-function-cannabis-users/) and reduce transition rates. For now, clinicians considering CBD in CHR populations should  |  Further Reading CED Clinic Blog[Cannabis-Infused Beverages as Alcohol Alternatives: New York at Five Years](https://cedclinic.com/cannabis-beverage-substitution-alcohol-new-york-five-years/) Research Digest[Daily Digest 2026-03-07](https://cedclinic.com/adolescent-cannabis-psychiatric-outcomes-2026-digest/) Cannabis Policy Wire[Policy Watch: 20 Regulatory Updates — March 10, 2026](https://cedclinic.com/dea-scheduling-synthetic-opioids-regulatory-updates-2026/) [View on PubMed ↗](https://pubmed.ncbi.nlm.nih.gov/41337954/)[DOI ↗](https://doi.org/10.1016/j.pscychresns.2025.112095) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) RELATED READING AT CED CLINIC Continue exploring the evidence [Cannabidiol Effects on Glutamate and Learning in Psychosis Prevention](https://cedclinic.com/cannabidiol-clinical-trials-psychosis-research/) This article explores how cannabidiol affects glutamate neurotransmission and learning processes relevant to psychosis prevention. [Read More](https://cedclinic.com/cannabidiol-clinical-trials-psychosis-research/) [endocannabinoid system clinical research: CBD & psychosis](https://cedclinic.com/cbd-hippocampal-glutamate-modulation-psychosis/) An overview of [clinical research](https://cedclinic.com/cannabis-based-therapies-smoking-cessation/) on the endocannabinoid system's role in psychosis and the therapeutic potential of CBD. [Explore Research](https://cedclinic.com/cbd-hippocampal-glutamate-modulation-psychosis/) [Cannabidiol Clinical Trials: High Risk Psychosis Research](https://cedclinic.com/cannabidiol-clinical-trials-psychosis-research/) Review of [clinical trials](https://cedclinic.com/endocannabinoid-system-emotional-memory-ptsd-treatment/) investigating cannabidiol's effects in individuals at high risk for psychosis. [Learn More](https://cedclinic.com/cannabidiol-clinical-trials-psychosis-research/) Have thoughts on this? Share it: [X Share on X](https://twitter.com/intent/tweet?text=Cannabinoid%20Clinical%20Trials%3A%20CBD%2C%20Psychosis%20%26%20Brain%20Function&url=https%3A%2F%2Fcedclinic.com%2Fcbd-hippocampal-glutamate-modulation-psychosis-risk%2F) [in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A%2F%2Fcedclinic.com%2Fcbd-hippocampal-glutamate-modulation-psychosis-risk%2F) [Share on BlueSky](https://bsky.app/intent/compose?text=Cannabinoid%20Clinical%20Trials%3A%20CBD%2C%20Psychosis%20%26%20Brain%20Function%20https%3A%2F%2Fcedclinic.com%2Fcbd-hippocampal-glutamate-modulation-psychosis-risk%2F) [Follow on Instagram](https://www.instagram.com/drbenjamincaplan) [Read more on Substack](https://doctorapprovedcannabis.substack.com/) [Subscribe via RSS](https://cedclinic.com/feed/) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).